INKT - MiNK P/S Multiple

Brandmark of MiNK Therapeutics, Inc (INKT)

MiNK Therapeutics, Inc. (INKT) conducts immunotherapy research and development, completely ignoring economic cycles and GDP fluctuations. The primary growth driver is the clinical trials of the agenT-797 drug for the treatment of pneumonia and lung cancer. The company's P/S ratio reflects the current business valuation, with the 237.60 level serving as a critical benchmark. The early stage of allogeneic technologies results in high research expenses and a lack of profitability.

INKT (MiNK) Price-to-Revenue Ratio history from 11/14/2026 to 11/18/2026

MiNK (INKT) - metric breakdowns and financial figures

- market price and analyst price targets:
General company analysis:MiNK Therapeutics, INKT
Manufactured product of MiNK Therapeutics Inc.

A fundamental stress test of assets requires comparing the issuer's market value with its actual earnings. MiNK Therapeutics, Inc. (INKT) is developing a proprietary allogeneic platform using hybrid immune cells for oncology therapy. An analysis of the company's industry-average P/S ratio allows for an assessment of the capitalization-to-annual-revenue ratio, revealing the extent of priced-in growth expectations. A high multiple here signals confidence in innovation but increases the risk of a collapse if financial targets are not met.